Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 270Stomach Neoplasms 200Rectal Neoplasms 180Pancreatic Neoplasms 131Colonic Neoplasms 112Neoplasm Metastasis 74Esophageal Neoplasms 63Carcinoma, Hepatocellular 41Neoplasms 40Cholangiocarcinoma 36Adenocarcinoma Of Esophagus 32Adenocarcinoma 32Biliary Tract Neoplasms 25Liver Neoplasms 21Gallbladder Neoplasms 21Recurrence 18Gastrointestinal Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Peritoneal Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Esophageal Squamous Cell Carcinoma 14Locally Advanced Rectal Cancer 12Bile Duct Neoplasms 11Colorectal Cancer Metastatic 8Unspecified Adult Solid Tumor, Protocol Specific 7Ovarian Neoplasms 7Lymphoma, Extranodal NK-T-Cell 7Head and Neck Neoplasms 7Appendiceal Neoplasms 7

Interventions

anlotinib 1S 1 (combination) 1Oxaliplatin 1Irinotecan 1Immune Checkpoint Inhibitors 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Overall Survival × Oxaliplatin × Clear all
NCT03726021 2023-03-29

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Completed
47 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡